Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma

Liu,Yang; Zhou,Yang; Zhang,Xiu-Shi; Shen,Bao-Zhong

doi:10.3892/ol.2011.384

Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma

Authors:
- Yang Liu
- Yang Zhou
- Xiu-Shi Zhang
- Bao-Zhong Shen
View Affiliations

Affiliations: Department of Radiology, The 3rd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Medical Imaging and Nuclear Medicine, The 4th Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: August 17, 2011 https://doi.org/10.3892/ol.2011.384
Pages: 1171-1175

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to investigate the association of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) expression with the histopathological grading of tumors in cerebral glioma. A total of 45 patients with pathologically confirmed cerebral glioma were divided into two groups: a low-grade group (grades I and II, 21 cases) and a high-grade group (grades III and IV, 24 cases). Immunohistochemical staining of tumor samples showed the percentages of tumors expressing VEGF and MMP-9 in the high-grade group to be 95.83 and 75%, respectively, significantly higher than those of the low-grade group (66.67 and 23.81%, P<0.05 and P<0.01, respectively). The magnetic resonance imaging (MRI) results indicated that the peripheral edema index (EI), enhancement percentage (EP), and the maximum diameter of the tumor in the high-grade group were significantly higher than those in the low-grade group (P<0.05, P<0.01, and P<0.05). Moreover, the expression of VEGF and MMP-9 was positively correlated with EI, EP and the maximum diameter of the tumor (P<0.05). Therefore, VEGF and MMP-9 expression were correlated to the invasion of glioma. The association of their expression levels with EI, EP and the maximum tumor diameter indicates that these markers may be used to estimate tumor malignancy for future clinical diagnosis and treatment.

View Figures

View References

1	Weller M, Felsberg J, Hartmann C, et al: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 27:5743–50. 2009. View Article : Google Scholar
2	Arany Z, Foo SY, Ma Y, et al: HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 alpha. Nature. 451:1008–1012. 2008. View Article : Google Scholar : PubMed/NCBI
3	Zheng SQ, Huang RQ and Zhang YJ: Role of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factor C in lymph node metastasis of breast cancer [J]. Zhonghua Bing Li Xue Za Zhi. 39:240–244. 2010.PubMed/NCBI
4	Sulman EP and Aldape K: The use of global profiling in biomarker development of gliomas. Brain Pathol. 21:88–95. 2011. View Article : Google Scholar : PubMed/NCBI
5	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
6	Inamura T, Nishio S, Takeshita I, Fujiwara S and Fukui M: Peritumoral brain edema in meningiomas influence of vascular supply on its development. Neurosurgery. 31:179–185. 1992. View Article : Google Scholar : PubMed/NCBI
7	Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, Kaiser HJ, Langen KJ and Eble MJ: Integrated-boost IMRT or 3-D-CRT using PET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison. Radiat Oncol. 4:572009.
8	Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G and Vecht C: Glioblastoma in adults. Crit Rev Oncol Hematol. 67:139–152. 2008. View Article : Google Scholar
9	Chan ES and Yeh MM: The use of immunohistochemistry in liver tumors. Clin Liver Dis. 14:687–703. 2010. View Article : Google Scholar : PubMed/NCBI
10	Sethi K, Sarkar S, Das S, Mohanty B and Mandal M: Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol. 8:341–352. 2010.PubMed/NCBI
11	Chen W and Silverman DH: Advances in evaluation of primary brain tumors. Semin Nucl Med. 38:240–250. 2008. View Article : Google Scholar : PubMed/NCBI
12	Costello JF: DNA methylation in brain development and gliomagenesis. Front Biosci. 8:s175–s184. 2003. View Article : Google Scholar : PubMed/NCBI
13	Diamandis EP, Fritsche HA, Lilja H, Daniel WC and Schwartz MK: Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. AACC press; Washington DC: pp. 172002
14	Puduvalli VK and Sawaga R: Antiangiogenesis therapeutic stragegios and clinical implications for brain tumors. J Neurooncol. 50:189–200. 2000. View Article : Google Scholar : PubMed/NCBI
15	Amãlinei C, Cãruntu ID, Giuscã SE and Bãlan RA: Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol. 51:215–228. 2010.
16	Savinov AY and Strongin AY: Matrix metalloproteinases, T cell homing and beta-cell mass in type 1 diabetes. Vitam Horm. 80:541–562. 2009. View Article : Google Scholar : PubMed/NCBI
17	Martin MD and Matrisian LM: The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 26:717–724. 2007. View Article : Google Scholar : PubMed/NCBI
18	Langer A: A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res. 10:283–299. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chen CQ, Liao WH and Chen CY: Correlation between peritumoral edema on MRI, VEGF expression, MVD and pathological grading in astrocytomas. Chin J Mod Med. 14:38–43. 2004.
20	Deng GX, Zhang H and Qian LX: Ordinal logistic regression analysis of MRl and pathological grade in astrocytoma. Chin Remed Clin. 5:680–682. 2005.
21	Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart JE Jr and Gladson CL: ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther. 6:454–462. 2007. View Article : Google Scholar : PubMed/NCBI